DexCom, Inc. (0A4M.L)

76.43 +1.21 (+1.61%) At close: 07:14PM BST

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Sector(s): 
Industry: 
Full-time employees: 6,300

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Kevin Ronald Sayer	Exec. Chairman, CEO & Pres	2.39M	N/A	1958
Mr. Jereme M. Sylvain	Exec. VP, CFO & Chief Accounting Officer	783.16k	N/A	1980
Mr. Jacob Steven Leach	Exec. VP & CTO	915.93k	N/A	1978
Mr. Chad M. Patterson	Exec. VP of Global Marketing	770.49k	N/A	1982
Mr. Paul R. Flynn	Exec. VP of Global Revenue	761.52k	N/A	1969
Mr. Barry J. Regan	Exec. VP of Global Operations	N/A	N/A	1973
Mr. Shelly Ramasamy Selvaraj	Sr. VP & Chief Information Officer	N/A	N/A	1959
Mr. Sean Christensen	Director of Corp. Affairs & Head of Investor Relations	N/A	N/A	N/A
Mr. Michael Brown	Exec. VP & Chief Legal Officer	N/A	N/A	1970
Mr. Matthew Dolan	Sr. VP of Strategy, Corp. Devel. & New Markets	N/A	N/A	1981

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Corporate governance

DexCom, Inc.’s ISS governance QualityScore as of 1 July 2022 is 8. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.